Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Loncastuximab Tesirine for the Treatment of Previously Treated Waldenstrom Macroglobulinemia

Trial Status: active

This phase II trial tests whether loncastuximab tesirine works in treating patients with Waldenstrom macroglobulinemia. Loncastuximab tesirine is a type of therapy called an antibody drug conjugate. Loncastuximab tesirine is a monoclonal antibody, called loncastuximab, linked to a drug, called pyrrolobenzodiazepine (PBD). Loncastuximab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers PBD to kill them.